PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.
American College of Surgeons Clinical Congress 2023
| Presentation Title: |
Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter, and Multinational Clinical Trial |
| Presenter: |
Shmuel Sharoni, M.D. |
| Date/Time: |
October 23, 2023/4:15 PM - 5:45 PM Eastern Time |
| Location: |
Session SF120 – Colon and Rectal Surgery I
BCEC Ballroom East, Level 3 |
The abstract will be available on www.polypid.com once the conference concludes.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
Source: PolyPid Ltd.
